Company profile for NOBO Medicine

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

NOBO Medicine, founded in 2017 as Genome Opinion, has rapidly grown into a biotech innovator. It developed the NOBO_VERSE disease database and partnered with major pharma companies like Yuhan and Hanmi. The company rebranded in 2023, acquired Emricasan, and advanced clinical programs, including a DLBCL therapy. In 2024, it in-licensed Poseltinib, reported Phase II data at ASCO, and secured IND approval in South Korea. With its...
NOBO Medicine, founded in 2017 as Genome Opinion, has rapidly grown into a biotech innovator. It developed the NOBO_VERSE disease database and partnered with major pharma companies like Yuhan and Hanmi. The company rebranded in 2023, acquired Emricasan, and advanced clinical programs, including a DLBCL therapy. In 2024, it in-licensed Poseltinib, reported Phase II data at ASCO, and secured IND approval in South Korea. With its precision medicine platform, NOBO aims to identify patients most likely to benefit from treatment, boosting drug development success and addressing unmet needs in cancer and chronic diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
South Korea
Address
Address
48, Achasan-ro 17-gil, Seongdong-gu, Seoul,Seongsu SK V One Center, 1st Buildi...
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

euroPLX 90 Lisbon

Not Confirmed

envelop Contact Supplier

euroPLX 90 Lisbon

Post an Enquiry

Meeting

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty